They say, for the first time, a drug has been shown to be so effective against obesity that patients may dodge many of its worst consequences, including Diabetes
It facilitates the development and function of immune cells including white blood cells to combat against microbes and foreign bodies
Clinical Trial Insights In SURMOUNT-1 and SURPASS trials, Mounjaro showed: Up to 22.5% body weight reduction in non-diabetic obese patients Greater HbA1c reductions vs Ozempic and insulin in diabetics Reference : Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Reference : mounjaro.lilly.com/hcp/a1c-weight FDA approved Mounjaro for Type 2 Diabetes in 2022, and later for weight loss under the brand Zepbound in Nov 2023 (US)
Also, there was a non-tumour specific reduction of CD27 + /CD11b + and an increase of CD27 + /CD11b , a subset of NK cells, in the tumoural and non-tumoural hemisphere, bone marrow, and spleen of the model mice [216]
The patients suitability is a key factor as is the expertise of the professional performing the treatments
